CN117377676A - 嘌呤衍生物的晶型及其药物组合物 - Google Patents
嘌呤衍生物的晶型及其药物组合物 Download PDFInfo
- Publication number
- CN117377676A CN117377676A CN202280037062.2A CN202280037062A CN117377676A CN 117377676 A CN117377676 A CN 117377676A CN 202280037062 A CN202280037062 A CN 202280037062A CN 117377676 A CN117377676 A CN 117377676A
- Authority
- CN
- China
- Prior art keywords
- dna
- compound
- present
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title abstract description 3
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 229940126289 DNA-PK inhibitor Drugs 0.000 claims abstract description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 30
- 230000005855 radiation Effects 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 9
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 229940126062 Compound A Drugs 0.000 description 24
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 24
- 239000008186 active pharmaceutical agent Substances 0.000 description 24
- 229940088679 drug related substance Drugs 0.000 description 23
- 239000007787 solid Substances 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000005782 double-strand break Effects 0.000 description 10
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 description 9
- 101710157074 DNA-dependent protein kinase catalytic subunit Proteins 0.000 description 9
- -1 Artemis Proteins 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 5
- QBOVXIMGMVOPQK-UHFFFAOYSA-N tert-butyl adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1(C(=O)OC(C)(C)C)C3 QBOVXIMGMVOPQK-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- ONWZXIPJHRFSOR-UHFFFAOYSA-N 2-chloro-4-[[3-[(2-methylpropan-2-yl)oxycarbonyl]-1-adamantyl]amino]pyrimidine-5-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)NC1=NC(=NC=C1C(=O)O)Cl ONWZXIPJHRFSOR-UHFFFAOYSA-N 0.000 description 3
- 229910017488 Cu K Inorganic materials 0.000 description 3
- 229910017541 Cu-K Inorganic materials 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- FQFZASRJFRAEIH-UHFFFAOYSA-N adamantane-1-carbonitrile Chemical compound C1C(C2)CC3CC2CC1(C#N)C3 FQFZASRJFRAEIH-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- IQJFXWFZPQVOFQ-UHFFFAOYSA-N tert-butyl 3-aminoadamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2(N)CC1(C(=O)OC(C)(C)C)C3 IQJFXWFZPQVOFQ-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- VCPKJMSVPCWFDW-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carbonitrile Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C#N)=O VCPKJMSVPCWFDW-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OXYLQJOHAIRRDV-UHFFFAOYSA-N CCOC(C(C(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)=N1)=CN=C1Cl)=O Chemical compound CCOC(C(C(NC(CC(C1)C2)(CC1C1)CC21C(OC(C)(C)C)=O)=N1)=CN=C1Cl)=O OXYLQJOHAIRRDV-UHFFFAOYSA-N 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000005768 DNA-Activated Protein Kinase Human genes 0.000 description 2
- 108010006124 DNA-Activated Protein Kinase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 description 2
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- PPOLOAZGUUWBKL-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxamide Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C(=O)N)=O PPOLOAZGUUWBKL-UHFFFAOYSA-N 0.000 description 1
- MFZJAPNMIQNMDL-UHFFFAOYSA-N 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylic acid Chemical compound CN1C(N(C2=NC(=NC=C12)NC=1C(=CC=2N(C=1)N=CN=2)C)C12CC3(CC(CC(C1)C3)C2)C(=O)O)=O MFZJAPNMIQNMDL-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- IGKDOJNYCDGKOZ-UHFFFAOYSA-N 7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-amine Chemical compound CC1=CC2=NC=NN2C=C1N IGKDOJNYCDGKOZ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101150059802 KU80 gene Proteins 0.000 description 1
- 102000015335 Ku Autoantigen Human genes 0.000 description 1
- 108010025026 Ku Autoantigen Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 101100342585 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-51 gene Proteins 0.000 description 1
- 101100074054 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mus-52 gene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100342589 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pku70 gene Proteins 0.000 description 1
- 101100074057 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pku80 gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- CKBZJTAMRPPVSR-UHFFFAOYSA-N adamantane-1-carboxamide Chemical compound C1C(C2)CC3CC2CC1(C(=O)N)C3 CKBZJTAMRPPVSR-UHFFFAOYSA-N 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- SRJBDGLSCPDXBL-UHFFFAOYSA-N ethyl 2,4-dichloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1Cl SRJBDGLSCPDXBL-UHFFFAOYSA-N 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150085005 ku70 gene Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000033863 telomere maintenance Effects 0.000 description 1
- BGJLIQQLHUDEMT-UHFFFAOYSA-N tert-butyl 3-(2-chloro-7-methyl-8-oxopurin-9-yl)adamantane-1-carboxylate Chemical compound ClC1=NC=C2N(C(N(C2=N1)C12CC3(CC(CC(C1)C3)C2)C(=O)OC(C)(C)C)=O)C BGJLIQQLHUDEMT-UHFFFAOYSA-N 0.000 description 1
- OIWKVIDPEPOKCT-UHFFFAOYSA-N tert-butyl 3-(2-chloro-8-oxo-7H-purin-9-yl)adamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2NC1=O)Cl OIWKVIDPEPOKCT-UHFFFAOYSA-N 0.000 description 1
- ZZZSDNNUFWIXBC-UHFFFAOYSA-N tert-butyl 3-[7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxopurin-9-yl]adamantane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)C12CC3(CC(CC(C1)C3)C2)N1C2=NC(=NC=C2N(C1=O)C)NC=1C(=CC=2N(C=1)N=CN=2)C ZZZSDNNUFWIXBC-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及取代的嘌呤衍生物的晶型及其药物组合物,制备方法和用于制备DNA‑PK抑制剂的用途。具体涉及式(A)所示化合物的晶型及其药物组合物,制备方法和用于制备DNA‑PK抑制剂的用途。
Description
本发明涉及一种嘌呤衍生物,或其水合物、溶剂化物的晶型,以及其制备方法或其药物组合物和其在制备DNA-PK抑制剂领域的用途。
DNA依赖的蛋白激酶(DNA-dependent protein kinase,DNA-PK)是由Ku70/Ku80异二聚体和DNA依赖的蛋白激酶催化亚基(DNA-PKcs)构成的DNA-PK酶复合物。该酶复合物需要在DNA参与下才能被激活发挥出相应的功能(George et al.,2019)。作为一种丝氨酸/苏氨酸蛋白激酶,DNA-PK属于PIKK(phosphatidylinositol 3-kinase-related kinase)家族成员,它不仅在修复细胞内DNA双链断裂(double-strand breaks;DSBs)和细胞DNA重组或抗体DNA重排(V(D)J重组)过程中具有重要作用,还参与染色体修饰、转录调节、端粒维持等生理过程。
在正常生理过程中,多种因素可能导致DNA发生DSBs:如体细胞DNA重组过程中DSBs常常作为中间产物出现,这一生理过程对所有脊椎动物的功能性免疫系统的形成十分重要;DNA复制中复制叉遇到受损的碱基,也可能造成单链或双链断裂;DNA也可能因为正常代谢过程中活性氧(reactive oxygen species;ROS)的攻击而产生DSBs(Cannan&Pederson,2016)。此外,还有多种外源性因素也可能导致DSBs,如电离辐射(Ionizing radiation,IR)和化疗试剂(如拓扑异构酶II抑制剂)等(George et al.,2019)。如果DSBs未被修复或者错误地修复,将会产生突变和/或染色体畸变,最终导致细胞死亡。为了应对DSBs带来的危害,真核细胞已进化出多种机制来修复受损的DNA以维持细胞的活力和基因组的稳定性。在真核细胞中,最主要的DNA修复方式是非同源末端连接(non-homologous end-joining,NHEJ)。这种直接将断裂DNA连接起来的方式并不需要有同源DNA片段参与,可以发生在细胞周期的任何阶段。NHEJ是由DNA-PK介导的需要多种蛋白与信号通路共同参与的动态过程,基本过程如下:(1)Ku70/Ku80异二聚体识别并结合至双链DNA断裂末端;(2)募集DNA-PKcs、XRCC4-DNA连接酶IV复合体等蛋白至DNA断裂双链的两侧;(3)DNA-PKcs自身 磷酸化,激活自身的激酶活性;(4)DNA-PKcs作为粘合剂连接断裂DNA的两端,防止核酸外切酶对DNA的降解作用;(5)对DNA进行加工以移除断裂处的不可连接末端或其他损伤形式;(6)XRCC4-DNA连接酶IV复合体修复DNA末端(某些情况下,在连接之前可能还需要DNA聚合酶来合成新的末端)。当DNA-PKcs发生磷酸化后,可诱导蛋白构象发生改变,调节NHEJ过程中多种蛋白的活性(如Artemis、Ku70、Ku80、DNA ligase),这对DNA修复过程至关重要。因此,磷酸化的DNA-PKcs(pDNA-PKcs)常常作为细胞DSBs的标志物。
已有研究表明,DNA-PK活性与多种肿瘤的发生发展有关:如黑色素瘤中的DNA-PKcs可以促进血管再生和肿瘤的转移;多发性骨髓瘤中的DNA-PKcs表达量显著上调;放疗耐受的甲状腺肿瘤中的Ku蛋白的含量明显增加(Ihara,Ashizawa,Shichijo,&Kudo,2019)。因此,可以考虑将DNA-PK抑制剂与引起DNA损伤的抗肿瘤疗法(如IR、化疗试剂等)联用来提高效果。DNA-PK抑制剂的使用在一定程度上会干扰正常细胞的DNA修复功能,然而正常细胞体内还存在多种DNA修复途径作为补充,而肿瘤细胞面临强大的DNA复制压力且缺乏有效的DNA修复方式。通过抑制肿瘤细胞DNA-PK的活性能够提高其他抗肿瘤药物对肿瘤细胞的杀伤效果。
发明内容
本发明提供了3-(7-甲基-2-[(7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基)氨基]-8氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-甲腈(化合物A)的晶型I和II,化合物A具有以下化学结构:
本发明的晶型表现出了以下至少一方面优势:溶解度好,稳定性高,易于处理、加工、提纯,改善药物口服生物利用度,延长药物储存期限,易于各种剂型制造。
本发明的晶型表现出优于化合物A的无定形态的制药学优势。尤其是,晶型增强了化学和物理的稳定性,更有利于在制备包含药理学活性成分的固体药物剂型。
本发明的晶形以原料药的约5重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约10重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约15重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约20重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约25重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约30重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约35重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约40重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约45重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约50重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约55重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约60重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约65重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约70重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约75重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约80重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约85重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约90重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约95重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约98重量%至约100重量%存在。在某些实施方案中,本发明的晶形以原料药的约99重量%至约100重量%存在。在某些实施方案中,基本上所有的原料药都是本发明的晶形,即原料药基本上是相纯晶体。
本发明化合物A无特殊说明,则为化合物A的无定形态。
本发明所述晶型的一个实施方案为无水化合物A(晶型I),使用Cu-Kα辐射,其X-射线粉末衍射图谱在以下2θ位置具有特征衍射峰:9.4472°±0.3°,18.836°±0.3°,23.79°±0.3°。
其中,该晶型I的X-射线粉末衍射中,2θ衍射角度还在7.414°±0.2°,13.514°±0.2°,15.119°±0.2°,15.43°±0.2°,16.601°±0.2°,23.496°±0.2°处具有特征衍射峰。
进一步的,该晶型I的X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:13.077°±0.2°,17.027°±0.2°,17.527°±0.2°,24.55°±0.2°,27.407°±0.2°。
再进一步,晶型I的X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:4.7909°±0.2°,10.404°±0.2°,13.790°±0.2°,18.01°±0.2°,21.389°±0.2°,22.064°±0.2°,25.154°±0.2°,25.912°±0.2°。
更进一步,该晶型I的X-射线粉末衍射图谱(XRD)基本如附图1所示。
本发明所述晶型的一个实施方案为无水化合物A(晶型II),使用Cu-Kα辐射,其X-射线粉末衍射图谱在以下2θ位置具有特征衍射峰:7.8763°±0.3°,16.633°±0.3°,18.059°±0.3°,27.085°±0.3°。
其中,该晶型II的X-射线粉末衍射中,2θ衍射角度还在11.619°±0.2°,17.075°±0.2°,22.088°±0.2°,27.915°±0.2°处具有特征衍射峰。
进一步的,该晶型II的X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:9.243°±0.2°,10.912°±0.2°,13.019°±0.2°,14.591°±0.2°,22.504°±0.2°,23.475°±0.2°。
再进一步,晶型II的X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:9.624°±0.2°,10.156°±0.2°,19.26°±0.2°,23.807°±0.2°,25.080°±0.2°。
更进一步,该晶型II的X-射线粉末衍射图谱(XRD)基本如附图2所示。
本发明还涉及一种药物组合物,包含治疗有效量的本发明中所述的晶型化合物,以及一种或多种药学上可接受的载体或赋形剂。
本发明所述的晶型作为活性药物成分,或其作为活性成分的药物组合物可以用于制备DNA-PK抑制剂药物。
其中,DNA-PK抑制剂用于制备治疗与预防癌症的药物。
本发明公开的X-射线粉末衍射图,与其实质上相同的也属于本发明的范围。
除非有相反的陈述,在说明书和权利要求书中使用的术语具有下述含义。
“有效剂量”指引起组织、系统或受试者生理或医学翻译的化合物的量,此量是所寻求的,包括在受治疗者身上施用时足以预防受治疗的疾患或病症的一种或几种症状发生或使其减轻至某种程度的化合物的量。
“IC
50”指半数抑制浓度,指达到最大抑制效果一半时的浓度。
本发明晶型结构可以使用本领域普通技术人员已知的各种分析技术分析,包括但 不限于X-射线粉末衍射(XRD)。
可以理解的是,本发明描述的和保护的数值为近似值。数值内的变化可能归因于设备的校准、设备误差、晶体的纯度、晶体大小、样本大小以及其他因素。
可以理解的是,本发明的晶型不限于与本发明公开的附图中描述的特征图谱完全相同的特征图谱,比如XRD,具有与附图中描述的哪些图谱基本上相同或本质上相同的特征图谱的任何晶型均落入本发明的范围内。
在不背离本发明的范围和主旨下,通过考虑本发明的说明书和实施例操作内容后,对本发明进行各种不同的改进和改变对本领域技术人员将是显而易见的。
图1是化合物A晶型I使用Cu-Kα辐射的X-射线粉末衍射图谱。
图2是化合物A晶型II使用Cu-Kα辐射的X-射线粉末衍射图谱。
以下通过具体实施例详细说明本发明的实施过程和产生的有益效果,旨在帮助阅读者更好地理解本发明的实质和特点,不作为对本案可实施范围的限定。
实施例中无特殊说明,溶液是指水溶液。
除非特殊说明,结晶的实验条件一般为室温(20-30℃,30-70%RH),溶剂比例是指体积比。
实施例1化合物A的制备
3-(7-甲基-2-[(7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基)氨基]-8氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-甲腈(化合物A)
3-(7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxo-8,9-dihydro-7H-purin-9-yl)adamantane-1-carbonitrile
第一步:
3-氨基金刚烷-1-羧酸叔丁酯(1b)
tert-butyl 3-aminoadamantane-1-carboxylate
将化合物1a(10g,51.21mmol)溶于氯化亚砜(70mL),90℃回流1h。将反应液直接浓缩,并用甲苯(50mL)复溶后浓缩除去多余的氯化亚砜,冰浴加入叔丁醇(60mL),随后室温反应1h,TLC监测至反应完全,直接将反应液浓缩,收集固体得到目标化合物1b(白色固体,12g,产率93.22%)。
LC-MS m/z(ESI)=252.20[M+1]。
第二步:
4-((3-(叔丁氧基羰基)金刚烷-1-基)氨基)-2-氯嘧啶-5-羧酸乙酯(1c)
ethyl4-(((1s,3r,5R,7S)-3-(tert-butoxycarbonyl)adamantan-1-yl)amino)-2-chloropyrimidine-5-carboxylate
将化合物2,4-二氯嘧啶-5-羧酸乙酯(12g,54.29mmol),化合物1b(13.65g,54.29mmol),碳酸钾(15.01g,108.58mmol)溶于乙腈(150mL),反应液在室温反应16h。TLC监测反应结束,过滤,并用少量乙腈清洗固体,将滤液合并后浓缩,粗品经柱层析分离(石油醚/乙酸乙酯(v/v)=1/1)后得到目标化合物1c(白色固体,15g,产率63.38%)。
1H NMR(400MHz,DMSO-d
6)δ8.63(s,1H),8.36(s,1H),4.30(q,2H),2.00–2.18(m,8H),1.61-1.73(m,6H),1.38(s,9H),1.31(t,3H)。
第三步:
4-((3-(叔丁氧基羰基)金刚烷-1-基)氨基)-2-氯嘧啶-5-羧酸(1d)
4-((3-(tert-butoxycarbonyl)adamantan-1-yl)amino)-2-chloropyrimidine-5-carboxylicacid
将化合物1c(15g,34.41mmol)溶解于四氢呋喃200mL,水200mL中,加入氢氧化锂(1.65g,68.82mmol),室温搅拌1h。TLC监测反应完全,浓缩除去四氢呋喃,用6N盐酸调pH为5,有白色固体析出,过滤,滤饼用石油醚洗两次,搜集固体得到标题化合物1d(白色固体,14g,产率99.75%)。
1H NMR(400MHz,DMSO-d
6)δ8.65(s,1H),8.58(s,1H),2.01–2.17(m,8H),1.57–1.77(m,6H),1.38(s,9H)。
LC-MS m/z(ESI)=408.10[M+1]。
第四步:
3-(2-氯-8-氧代8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-羧酸叔丁酯(1e)
tert-butyl-3-(2-chloro-8-oxo-8,9-dihydro-7H-purin-9-yl)adamantane-1-carboxylate
将化合物1d(15g,36.77mmol)溶于N,N-二甲基乙酰胺(150mL)中,冰浴加入叠氮磷酸二苯酯(7.91mL,36.77mmol)和三乙胺(5.11mL,36.77mmol),将反应液室温搅拌1h后升温至120℃继续反应3h。TLC监测反应完全(二氯甲烷/甲醇(v/v)=4/1),将反应液自然冷却至室温,缓慢倒入600mL冰水中,出现大量固体,过滤,收集固体,且用乙酸乙酯(150mL)打浆,真空干燥得到目标化合物1e(白色固体,7.0g,产率47.02%)。
1H NMR(400MHz,DMSO-d
6)δ11.56(s,1H),8.07(s,1H),2.44–2.57(m,6H),2.23(s,2H),1.58–1.80(m,6H),1.39(s,9H)。
第五步:
叔丁基3-(2-氯-8-氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-羧酸叔丁酯(1f)
tert-butyl3-(2-chloro-7-methyl-8-oxo-8,9-dihydro-7H-purin-9-yl)adamantane-1-carboxylate
将化合物1e(5g,12.35mmol)溶于二甲基甲酰胺(40mL)中,在0℃下加入碳酸铯(6.04g,18.52mL)和硫酸二甲酯(1.4mL,14.82mmol),室温反应2h。TLC监测至反应完全,加入100ml水,析出固体,过滤,干燥得到目标化合物1f(白色固体,5.0g,产率96.64%)。
1H NMR(400MHz,DMSO-d
6)δ8.31(s,1H),3.29(s,3H),2.43–2.56(m,6H),2.24(s,2H),1.54–1.80(m,6H),1.38(s,9H)。
第六步:
叔丁基3-(7-甲基-2-[(7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基)氨基]-8-氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-羧酸叔丁酯(1g)
tert-butyl3-(7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxo-8,9-dihydro-7H-purin-9-yl)adamantane-1-carboxylate
将7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-胺(500mg,3.37mmol)、化合物1f(1.41g,3.37mmol)、碳酸铯(2.31g,7.08mmol)、[(2-二-环己基膦基-3,6-二甲氧基-2′,4′,6′-三异丙基-1,1′-联苯基)-2-(2′-氨基-1,1′-联苯基)]甲磺酸钯(II)甲磺酸酯(310mg,0.34mmol)溶解于二氧六环(10mL),氮气保护并换气,在100℃搅拌4h。TLC监测反应结束,将反应液倒入冰水中,搜集固体,将固体用硅胶柱色谱分离提纯(二氯甲烷/甲醇(v/v)=100/1),得到目标化合物1g(白色固体,1.4g,产率78.29%)。
1H NMR(400MHz,DMSO-d
6)δ9.08(s,1H),8.58(s,1H),8.36(s,1H),8.10(s,1H),7.68(s,1H),3.24(s,3H),2.33-2.61(m,6H),2.14(s,2H),1.51-1.67(m,6H),1.32(s,9H)。
LC-MS m/z(ESI)=531.3[M+1]。
第七步:
3-(7-甲基-2-((7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基]氨基]氨基)-8-氧代-7,8-二氢-9H-嘌呤-9-基)金刚烷-1-羧酸(1h)
3-(7-methyl-2-((7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino)-8-oxo-7,8-dihydro-9H-purin-9-yl)adamantane-1-carboxylic acid
将化合物1g(1.4g,2.64mmol)溶于4N盐酸二氧六环溶液(100mL),混合物室温反应16h后,浓缩,经中压制备后得到目标化合物1h(浅黄色固体,1.4g,产率99%)。
1H NMR(400MHz,DMSO-d
6)δ12.15(s,1H),9.07(s,1H),8.57(s,1H),8.36(s,1H),8.09(s,1H),7.68(s,1H),3.24(s,3H),2.41-2.58(m,6H),2.38(s,3H),2.14(s,2H),1.56–1.71(m,6H)。
LC-MS m/z(ESI)=475.20[M+1]。
第八步:
3-(7-甲基-2-[(7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基)氨基]-8-氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-甲酰胺(1i)
3-(7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxo-8,9-dihydro-7H-purin-9-yl)adamantane-1-carboxamide
将化合物1h(0.5g,1.05mmol),氯化铵(0.56g,10.50mmol),三乙胺(0.73mL,5.25mmol)溶于N,N-二甲基甲酰胺(15mL),冰浴加入HATU(0.6g,1.58mmol),混合物室温反应1h,加水(30mL)淬灭反应,乙酸乙酯(30mL×3)萃取,有机相干燥浓缩得到目标化合物1i(白色固体,0.14g,产率28.16%)。
1H NMR(400MHz,DMSO-d
6)δ9.08(s,1H),8.56(s,1H),8.36(s,1H),8.08(s,1H),7.68(s,1H),6.97(s,1H),6.74(s,1H),3.24(s,3H),2.33-2.62(m,9H),2.15(s,2H),1.51-1.73(m,4H)。
LC-MS m/z(ESI)=474.3[M+1]。
第九步:
3-(7-甲基-2-[(7-甲基-[1,2,4]三唑并[1,5-a]吡啶-6-基)氨基]-8氧代-8,9-二氢-7氢-嘌呤-9-基)金刚烷-1-甲腈(化合物A)
3-(7-methyl-2-[(7-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-8-oxo-8,9-dihydr o-7H-purin-9-yl)adamantane-1-carbonitrile
将化合物1i(130mg,0.27mmol)溶于二氯甲烷(20mL),冰浴加入吡啶(90mg,1.08mmol),三氟乙酸酐(170mg,0.81mmol),保持温度继续反应1h,加入甲醇(20mL),浓缩粗品。将粗品复溶解于乙酸乙酯(50mL),分别用15%NaHCO
3(50mL),饱和食盐水(50mL),干燥,浓缩得到化合物A(浅黄色固体,60mg,产率48.78%)。
1H NMR(400MHz,DMSO-d
6)δ9.07(s,1H),8.65(s,1H),8.37(s,1H),8.11(s,1H),7.70(s,1H),3.25(s,3H),2.75(s,2H),2.44-2.51(m,4H),2.38(s,3H),2.15(s,2H),1.91-1.94(m,4H),1.53-1.62(m,2H)。
LC-MS m/z(ESI)=456.2[M+1]。
实施例2化合物A晶型I的制备
化合物A在二氯甲烷中重结晶,得到化合物A的晶型I样品。
实施例3化合物A晶型II的制备
化合物A在二氯甲烷/甲醇(体积比9/1)混合溶液中重结晶,得到化合物A的晶型II样品。
测试例1
将化合物A的晶型I和II用日本Rigbu xtalab协同衍射仪,室温下石墨单色Cu-Kα辐射(λ=1.54),电压45KV,电流40mA,扫描范围(2θ角)3°-60°,获得粉末衍射图。使用Olex2,结构通过SHELXT结构解析程序,采用SHELXL-97直接方法对数据包进行最小方差精析。
化合物A晶型I的X-射线粉末衍射数据如表1所示,化合物A晶型I的X-射线粉末衍射图如附图1所示。
表1化合物A晶型I的X-射线粉末衍射数据
峰号 | 2θ角(度) | 晶面间距 | 峰高 | 半峰宽 | 相对峰高 |
1 | 4.7909 | 18.430 | 1715 | 0.2631 | 5.00 |
2 | 7.414 | 11.914 | 8298 | 0.289 | 26.21 |
3 | 9.4472 | 9.3540 | 35184 | 0.2743 | 100.00 |
4 | 10.404 | 8.496 | 1611 | 0.280 | 5.28 |
5 | 10.78 | 8.199 | 212 | 0.59 | 1.29 |
6 | 11.964 | 7.392 | 633 | 0.286 | 2.28 |
7 | 13.077 | 6.7646 | 6619 | 0.285 | 18.76 |
8 | 13.514 | 6.5466 | 6458 | 0.311 | 20.02 |
9 | 13.790 | 6.416 | 1732 | 0.32 | 5.44 |
10 | 14.096 | 6.278 | 1420 | 0.27 | 3.86 |
11 | 15.119 | 5.855 | 5685 | 0.34 | 20.31 |
12 | 15.43 | 5.738 | 5114 | 0.41 | 21.84 |
13 | 16.601 | 5.3357 | 5661 | 0.372 | 21.97 |
14 | 17.027 | 5.2031 | 4245 | 0.274 | 12.15 |
15 | 17.527 | 5.056 | 2258 | 0.49 | 11.48 |
16 | 18.01 | 4.921 | 1656 | 0.34 | 5.86 |
17 | 18.23 | 4.862 | 1212 | 0.28 | 3.48 |
18 | 18.836 | 4.7075 | 7500 | 0.462 | 36.15 |
19 | 19.702 | 4.5024 | 1669 | 0.261 | 4.54 |
20 | 20.471 | 4.335 | 566 | 0.20 | 1.20 |
21 | 21.389 | 4.1509 | 1832 | 0.48 | 9.24 |
22 | 22.064 | 4.0254 | 1835 | 0.300 | 5.75 |
23 | 23.496 | 3.7832 | 8375 | 0.289 | 24.08 |
24 | 23.79 | 3.737 | 6576 | 0.60 | 39.02 |
25 | 24.55 | 3.623 | 1337 | 0.9 | 12.22 |
26 | 25.154 | 3.5375 | 3029 | 0.293 | 8.83 |
27 | 25.912 | 3.4357 | 2677 | 0.367 | 9.78 |
28 | 26.676 | 3.3390 | 1176 | 0.23 | 2.66 |
29 | 27.407 | 3.2516 | 4893 | 0.337 | 16.41 |
30 | 28.39 | 3.141 | 668 | 0.69 | 4.62 |
31 | 29.454 | 3.0301 | 662 | 0.41 | 2.71 |
32 | 31.46 | 2.842 | 486 | 0.48 | 2.33 |
33 | 31.92 | 2.801 | 262 | 0.46 | 1.19 |
34 | 32.480 | 2.7544 | 1100 | 0.303 | 3.32 |
35 | 32.997 | 2.7124 | 776 | 0.29 | 2.26 |
36 | 33.402 | 2.6805 | 338 | 0.29 | 0.96 |
37 | 34.26 | 2.6152 | 336 | 0.33 | 1.09 |
38 | 35.28 | 2.5418 | 195 | 0.30 | 0.60 |
39 | 36.47 | 2.462 | 301 | 0.62 | 1.92 |
40 | 37.87 | 2.3739 | 366 | 0.41 | 1.55 |
41 | 41.113 | 2.1938 | 179 | 0.21 | 0.38 |
42 | 41.74 | 2.1620 | 80 | 0.22 | 0.17 |
43 | 42.50 | 2.1254 | 135 | 0.27 | 0.36 |
44 | 43.14 | 2.095 | 164 | 0.66 | 1.09 |
45 | 44.11 | 2.0513 | 163 | 0.24 | 0.40 |
46 | 45.49 | 1.992 | 224 | 0.41 | 0.97 |
47 | 45.97 | 1.9724 | 93 | 0.26 | 0.26 |
48 | 48.02 | 1.893 | 114 | 0.75 | 0.87 |
49 | 48.83 | 1.8635 | 265 | 0.36 | 0.97 |
50 | 50.71 | 1.7988 | 124 | 0.29 | 0.36 |
51 | 52.13 | 1.7530 | 159 | 0.59 | 0.94 |
52 | 53.27 | 1.7181 | 78 | 0.56 | 0.43 |
53 | 57.93 | 1.5905 | 55 | 0.8 | 0.86 |
化合物A晶型II的X-射线粉末衍射数据如表2所示,化合物A晶型II的X-射线粉末衍射图如附图2所示。
表2化合物A晶型II的X-射线粉末衍射数据
峰号 | 2θ角(度) | 晶面间距 | 峰高 | 半峰宽 | 相对峰高 |
1 | 4.01 | 22.0 | 37 | 0.94 | 1.69 |
2 | 4.860 | 18.17 | 291 | 0.203 | 2.86 |
3 | 5.50 | 16.06 | 85 | 0.40 | 1.64 |
4 | 7.8763 | 11.216 | 8195 | 0.2114 | 71.72 |
5 | 8.419 | 10.494 | 121 | 0.14 | 0.72 |
6 | 9.243 | 9.561 | 4450 | 0.198 | 34.85 |
7 | 9.624 | 9.183 | 1820 | 0.297 | 21.40 |
8 | 10.156 | 8.703 | 2964 | 0.205 | 24.06 |
9 | 10.912 | 8.102 | 3916 | 0.245 | 41.70 |
10 | 11.619 | 7.610 | 3444 | 0.335 | 50.28 |
11 | 13.019 | 6.794 | 3259 | 0.369 | 43.09 |
12 | 13.601 | 6.505 | 920 | 0.39 | 12.97 |
13 | 13.924 | 6.355 | 494 | 0.18 | 3.21 |
14 | 14.591 | 6.066 | 3074 | 0.293 | 32.32 |
15 | 14.828 | 5.9696 | 2286 | 0.170 | 13.95 |
16 | 15.075 | 5.872 | 1791 | 0.218 | 13.98 |
17 | 15.725 | 5.631 | 830 | 0.30 | 9.81 |
18 | 16.057 | 5.515 | 1519 | 0.21 | 12.49 |
19 | 16.633 | 5.325 | 4907 | 0.45 | 88.15 |
20 | 17.075 | 5.189 | 4877 | 0.298 | 57.80 |
21 | 18.059 | 4.908 | 5877 | 0.427 | 100.00 |
22 | 19.26 | 4.605 | 2245 | 0.26 | 23.17 |
23 | 19.52 | 4.543 | 842 | 0.18 | 6.02 |
24 | 20.38 | 4.354 | 843 | 0.22 | 6.52 |
25 | 20.6 | 4.32 | 992 | 0.29 | 10.34 |
26 | 21.553 | 4.120 | 1191 | 0.29 | 12.19 |
27 | 22.088 | 4.0211 | 3984 | 0.327 | 46.35 |
28 | 22.504 | 3.948 | 2719 | 0.33 | 31.68 |
29 | 22.88 | 3.883 | 1255 | 0.40 | 17.87 |
30 | 23.475 | 3.7866 | 4161 | 0.287 | 42.46 |
31 | 23.807 | 3.734 | 2391 | 0.33 | 27.78 |
32 | 25.080 | 3.548 | 2026 | 0.317 | 22.87 |
33 | 25.754 | 3.4564 | 1305 | 0.27 | 12.57 |
34 | 27.085 | 3.2895 | 6518 | 0.289 | 83.52 |
35 | 27.915 | 3.1935 | 2958 | 0.383 | 50.10 |
36 | 29.325 | 3.0431 | 223 | 0.29 | 2.28 |
37 | 31.639 | 2.8256 | 2103 | 0.142 | 18.64 |
38 | 32.57 | 2.747 | 119 | 0.22 | 1.47 |
39 | 33.960 | 2.6376 | 431 | 0.41 | 6.34 |
40 | 34.55 | 2.5940 | 483 | 0.48 | 8.29 |
41 | 35.74 | 2.510 | 118 | 0.23 | 1.38 |
42 | 36.40 | 2.466 | 243 | 0.72 | 8.94 |
43 | 39.05 | 2.305 | 139 | 0.28 | 2.12 |
44 | 42.82 | 2.110 | 280 | 1.28 | 14.97 |
45 | 45.353 | 1.9980 | 803 | 0.271 | 9.10 |
46 | 46.44 | 1.9536 | 164 | 0.42 | 2.88 |
47 | 48.34 | 1.881 | 88 | 0.33 | 1.04 |
48 | 50.10 | 1.819 | 91 | 0.37 | 1.43 |
49 | 50.68 | 1.800 | 99 | 0.44 | 1.81 |
50 | 52.62 | 1.738 | 64 | 0.38 | 0.87 |
51 | 56.450 | 1.62877 | 1675 | 0.073 | 6.17 |
测试例2
DNA-PK激酶抑制试验
通过DNA-PK激酶检测试剂盒(DNA-PK kinase assay kit)(购买自Promega公司,货号:V4107,批号:0000366495)检测化合物对DNA-PK激酶的抑制活性。利用化学发光对结果进行定量,具体实验方案如下:
i.按照试剂盒说明书构建不同浓度ADP-荧光标准曲线;
ii.于384孔白色板中制备5μL反应体系,每孔中分别加入1μL化合物A(分别设定浓度梯度1μM、200nM、40nM、8nM、1.6nM、0.32nM、0.064nM、0.013nM)、 20units DNA-PK激酶、0.2μg/μL底物、10μg/μL DNA、50μM ATP、1%DMSO;
iii.混匀,离心(1000rpm,30s),37℃孵育60min;
iv.加入5μL ADP‐Glo
TM Reagent终止反应,混匀,离心(1000rpm,30s),室温孵育40min;
v.加入10μL Kinase Detection Reagent,震荡混匀,离心(1000rpm,30s),室温孵育30min;
vi.利用酶标仪(Thermo fisher,Varioskan LUX)测定荧光值。利用GraphPad Prism8进行IC
50的计算,结果见表3。
表3化合物A对DNA-PK激酶抑制活性
化合物编号 | IC 50(nM) |
化合物A | 0.08 |
对照例 | 100.20 |
注:对照例为J.Med.Chem(2020),63(7),3461-3471的化合物3,对照例按照其制备方法制备得到。
结果表明,与对照例相比,本发明化合物对DNA-PK激酶具有更显著的抑制效果。
本发明说明书对具体实施方案进行了详细描述,本领域技术人员应认识到,上述实施方案是示例性的,不能理解为对本发明的限制,对于本领域技术人员来说,在不脱离本发明原理的前提下,通过对本发明进行若干改进和修饰,这些改进和修饰获得技术方案也落在本发明的权利要求书的保护范围内。
Claims (12)
- 式(A)所示化合物的晶体:
- 根据权利要求1所述的晶体,其特征在于,晶型I使用Cu-Kα辐射,其X-射线粉末衍射图谱在以下2θ位置具有特征衍射峰:9.4472°±0.3°,18.836°±0.3°,23.79°±0.3°。
- 根据权利要求2所述的晶体,其特征在于,晶型I使用Cu-Kα辐射,其X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:7.414°±0.2°,13.514°±0.2°,15.119°±0.2°,15.43°±0.2°,16.601°±0.2°,23.496°±0.2°。
- 根据权利要求3所述的晶体,其特征在于,晶型I使用Cu-Kα辐射,其X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:13.077°±0.2°,17.027°±0.2°,17.527°±0.2°,24.55°±0.2°,27.407°±0.2°。
- 根据权利要求4所述的晶体,其特征在于,晶型I的X-射线粉末衍射图谱如图1所示。
- 根据权利要求1所述的晶体,其特征在于,晶型II使用Cu-Kα辐射,其X-射线粉末衍射图谱在以下2θ位置具有特征衍射峰:7.8763°±0.3°,16.633°±0.3°,18.059°±0.3°,27.085°±0.3°。
- 根据权利要求6所述的晶体,其特征在于,晶型II使用Cu-Kα辐射,其X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:11.619°±0.2°,17.075°±0.2°,22.088°±0.2°,27.915°±0.2°。
- 根据权利要求7所述的晶体,其特征在于,晶型II使用Cu-Kα辐射,其X-射线粉末衍射图谱还在以下2θ位置具有特征衍射峰:9.243°±0.2°,10.912°±0.2°,13.019°±0.2°,14.591°±0.2°,22.504°±0.2°,23.475°±0.2°。
- 根据权利要求8所述的晶体,其特征在于,晶型II的X-射线粉末衍射图谱如 图2所示。
- 一种药物组合物,包含治疗有效量的权利要求1~9中任一项所述晶型,以及药学上可接受的载体或赋形剂。
- 权利要求1~9中任一项所述晶型,或权利要求10所述的药物组合物在制备DNA-PK抑制剂中的用途。
- 权利要求1~9中任一项所述晶型,或权利要求10所述的药物组合物在制备用于治疗与预防癌症的药物中的用途。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110714009 | 2021-06-29 | ||
CN202110714010 | 2021-06-29 | ||
CN2021107140101 | 2021-06-29 | ||
CN2021107140099 | 2021-06-29 | ||
PCT/CN2022/102452 WO2023274310A1 (zh) | 2021-06-29 | 2022-06-29 | 嘌呤衍生物的晶型及其药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117377676A true CN117377676A (zh) | 2024-01-09 |
Family
ID=84691443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280037062.2A Pending CN117377676A (zh) | 2021-06-29 | 2022-06-29 | 嘌呤衍生物的晶型及其药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117377676A (zh) |
WO (1) | WO2023274310A1 (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3558997T3 (da) * | 2016-12-20 | 2021-04-19 | Astrazeneca Ab | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer |
TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
CA3159290A1 (en) * | 2019-11-25 | 2021-06-03 | Kevin X Chen | Pyrimidoimidazole compounds used as dna-pk inhibitors |
JP7428806B2 (ja) * | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
CN114573605A (zh) * | 2020-12-01 | 2022-06-03 | 武汉光谷亚太医药研究院有限公司 | Dna依赖蛋白激酶抑制剂及其应用 |
-
2022
- 2022-06-29 WO PCT/CN2022/102452 patent/WO2023274310A1/zh active Application Filing
- 2022-06-29 CN CN202280037062.2A patent/CN117377676A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023274310A1 (zh) | 2023-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2604610B1 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
EP3572400B1 (en) | Ezh2 inhibitor and use thereof | |
EP2970254B1 (en) | Imidazo pyridine compounds | |
US7468382B2 (en) | Pyridine derivatives useful as inhibitors of PKC-theta | |
US20040248879A1 (en) | Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases | |
CN110759908A (zh) | 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用 | |
KR20120113709A (ko) | 벤조이미다졸 화합물 및 그의 용도 | |
TW201414744A (zh) | 胺基喹唑啉激酶抑制劑之前藥 | |
JP2016509051A (ja) | キナーゼ阻害剤としてのキナゾリン類 | |
EP4086257A1 (en) | Dual clk/cdk1 inhibitors for cancer treatment | |
JP2005508855A (ja) | オキサゾロ−およびフロピリミジンならびに腫瘍に対する医薬としてのその使用 | |
JP6927548B2 (ja) | ある種のタンパク質キナーゼ阻害剤 | |
BG61729B1 (bg) | 9-заместени-2-(2-норм-алкоксифенил)пурин-6-они | |
KR20230048106A (ko) | 스플라이싱을 조절하는 조성물 | |
WO2018041260A1 (zh) | 一类溴结构域识别蛋白抑制剂及其制备方法和用途 | |
US10501462B2 (en) | Pyrrolo[3,2-c]pyridine-6-amino derivatives | |
CN117377676A (zh) | 嘌呤衍生物的晶型及其药物组合物 | |
CN114907350B (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
EP3242881B1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
CN109384793B (zh) | 一种具有hdac6抑制活性的硫醇类化合物及其应用 | |
CN109761997B (zh) | 双-氟喹诺酮噻二唑脲类n-甲基洛美沙星衍生物的制备和应用 | |
WO2004108723A1 (en) | 4,5-dihydro-imidazo[4,5,1-ii]quinolin-6-ones as parp inhibitors | |
WO2020086650A2 (en) | Novel compounds | |
WO2021073494A1 (en) | The salts of a compound and the crystalline forms thereof | |
CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |